MedPath

VABOMERE

These highlights do not include all the information needed to use VABOMERE safely and effectively. See full prescribing information for VABOMERE. VABOMERE (meropenem and vaborbactam) for injection, for intravenous use Initial U.S. Approval: 2017

Approved
Approval ID

e237fd0f-3050-42a3-b43e-b6fb4824e93d

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 19, 2023

Manufacturers
FDA

Melinta Therapeutics, LLC

DUNS: 079949853

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Meropenem-Vaborbactam

PRODUCT DETAILS

NDC Product Code70842-120
Application NumberNDA209776
Marketing CategoryC73594
Route of AdministrationINTRAVENOUS
Effective DateSeptember 30, 2023
Generic NameMeropenem-Vaborbactam

INGREDIENTS (3)

VABORBACTAMActive
Quantity: 1 g in 2 g
Code: 1C75676F8V
Classification: ACTIB
MEROPENEMActive
Quantity: 1 g in 2 g
Code: FV9J3JU8B1
Classification: ACTIB
SODIUM CARBONATEInactive
Quantity: 575 mg in 2 g
Code: 45P3261C7T
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

VABOMERE - FDA Drug Approval Details